| Therapeutic drug monitoring and point-of-care technologies: Opportunities and current challenges | Therapeutic drug monitoring |  | | 2026 | 1 | 0 |
|
| Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective | Pharmaceutics | | | 2023 | 79 | 200 |
|
| From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure | Pharmaceutics | | | 2023 | 133 | 169 |
|
| Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation | The journal of antimicrobial chemotherapy |  | | 2022 | 107 | 0 |
|
| Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study | Multiple Sclerosis Journal | | | 2021 | 285 | 0 |
|
| The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib | Frontiers in Pharmacology | | | 2020 | 365 | 344 |
|
| Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review | Therapeutic Drug Monitoring | | | 2020 | 263 | 1 |
|
| Validation and Clinical Application of a Multiplex High Performance Liquid Chromatography - Tandem Mass Spectrometry Assay for the Monitoring of Plasma Concentrations of 12 Antibiotics in Patients with Severe Bacterial Infections | Journal of Chromatography. B | | | 2020 | 329 | 431 |
|
| Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry | Journal of Chromatography. B | | | 2018 | 284 | 0 |
|
| Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring | Journal of Pharmaceutical and Biomedical Analysis | | | 2018 | 247 | 2 |
|
| Guidance to develop individual dose recommendations for patients on chronic hemodialysis | Expert Review of Clinical Pharmacology | | | 2017 | 520 | 0 |
|
| Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid | Dermatology | | | 2017 | 431 | 0 |
|
| In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid | Drug Metabolism and Disposition | | | 2016 | 611 | 279 |
|
| Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial | Cancer chemotherapy and pharmacology | | | 2014 | 592 | 0 |
|
| Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals | Pharmacogenetics and genomics | | | 2013 | 670 | 0 |
|
| Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women | Antiviral therapy | | | 2013 | 607 | 0 |
|
| Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia | AIDS | | | 2012 | 677 | 0 |
|
| Pharmacovigilance in pregnancy: adverse drug reactions associated with fetal disorders | Journal of perinatal medicine | | | 2012 | 764 | 1,526 |
|
| Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma | The Journal of clinical endocrinology and metabolism | | | 2012 | 705 | 0 |
|
| ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir | Pharmacogenetics and genomics | | | 2010 | 711 | 0 |
|
| Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir | Antimicrobial agents and chemotherapy | | | 2009 | 637 | 0 |
|
| Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals | Clinical pharmacology and therapeutics | | | 2009 | 681 | 0 |
|
